Pay in 4 interest-free payments of $6.30 Learn more
Ships within 48 hours · Estimated delivery Nov 2 - Nov 7
Appointments Recommended
The SURMOUNT-1 trial showed 21.4% average body weight reduction at this dose level
One article found an increased incidence of aspiration pneumonia among GLP-1 users compared to non-users reporting a hazard ratio of 1.33 (95%CI 1.021.74, p = 0.036) (Australian Diabetes Society, National Association of Clinical Obesity Services, Gastroenterological Society of Australia, and Australian and New Zealand College of Anaesthetists n.d.)
This guide covers exact dosage protocols, reconstitution math, injection timing, a week-by-week results timeline, side effects, stacking options, and the only human clinical trial data available
This can help reduce unwanted body weight and improve energy/power output
Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models
